Oral IRAK4 inhibitor BAY-1834845 prevents acute respiratory distress syndrome

Acute respiratory distress syndrome (ARDS) is a lethal clinical entity that has become an emergency event with the outbreak of COVID-19. However, to date, there are no well-proven pharmacotherapies except dexamethasone. This study is aimed to evaluate IRAK4 inhibitors as a potential treatment for AR...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Qianqian, Li, Rui, Yin, Hanlin, Wang, Suli, Liu, Bei, Li, Jun, Zhou, Mi, Yan, Qingran, Lu, Liangjing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier Masson SAS. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9339262/
https://www.ncbi.nlm.nih.gov/pubmed/36076574
http://dx.doi.org/10.1016/j.biopha.2022.113459

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9339262/
https://www.ncbi.nlm.nih.gov/pubmed/36076574
http://dx.doi.org/10.1016/j.biopha.2022.113459

Ejemplares similares